Pfizer, BioNTech Begin Early-Stage Study On COVID-19-Influenza Combination Vaccine
Reuters (11/3, Satija) reports Pfizer and partner BioNTech “have started an early-stage study to evaluate a combination vaccine targeting COVID-19 and influenza, the companies said on Thursday.” This “single-dose vaccine candidate is a combination of Pfizer’s mRNA-based flu shot and the companies’ Omicron-tailored” bivalent “COVID-19 booster shot.”
The Hill (11/3, Choi) reports, “The study includes 180 adults between the ages of 18 and 64,” and “participants received their first doses of the vaccine candidate this week.”